Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract 4502).
Narjust Duma, MD, of the Carbone Cancer Center at the University of Wisconsin, Madison, and Gladys I. Rodriguez, MD, of South Texas Oncology and Hematology, talk about the underrepresentation of Hispanic individuals in medicine, especially in oncology, and their efforts to create the first Young Investigator Award in Recognition of an Outstanding Latina Researcher to encourage Hispanic women to enter medicine and cancer research.
Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the outcome of a trial that explored maintenance therapy with ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Toxicities unrelated to the maintenance treatment forced the trial to close prematurely (Abstract 7003).
Debora S. Bruno, MD, of Seidman Cancer Center at Cleveland Medical Center, discusses study findings that show Black patients with advanced or metastatic non–small cell lung cancer tend to be less likely to undergo biomarker testing or to be treated in clinical trials than White patients. Recommended broad-based testing, says Dr. Bruno, may help ensure equal access to quality care and clinical trials (Abstract 9005).
Massimo Cristofanilli, MD, of the Feinberg School of Medicine at Northwestern University, discusses updated overall survival data from the phase III PALOMA-3 trial of palbociclib plus fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract 1000).
